FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

**OMB APPROVAL** 3235-0287

Check this box if no longer subject to									
Section 16. Form 4 or Form 5									
obligations may continue. See									
Instruction 1(b).									

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden hours per response: 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(c). Se	ee Instruction	10.																
Name and Address of Reporting Person*     Milnes Alistair						2. Issuer Name and Ticker or Trading Symbol BICYCLE THERAPEUTICS PLC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
,														Officer (gi <sup>.</sup> below)	ive title	Other below)	(specify	
(Last) (First) (Middle)  C/O BICYCLE THERAPEUTICS PLC  BLOCKS A & P. POPTWAY PLUI DING						3. Date of Earliest Transaction (Month/Day/Year) 10/03/2024								CHIEF OPERATING OFFICER				
BLOCKS A & B, PORTWAY BUILDING					4. If <i>i</i>	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street) CAMBRIDGE X0 CB21 60			6GS									Line)  Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City)	(8	state) (2	Zip)															
		Table	1 - No	on-Deriva	tive :	Secu	rities Ad	quire	d, Dis	sposed of	, or E	Benefic	ially C	wned				
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/Y						Execution Date,		Transaction I Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			and 5) Securi Benefi		y   F	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Ti	ransaction nstr. 3 and			(111501. 4)	
Ordinary Shares 10/03/20.					024	24		<b>S</b> <sup>(1)</sup>		972	D	\$22.2	26(2)	70,30	)2	D		
		Та	ble II							osed of, convertib				vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	3A. Deemed Execution Date, if any (Month/Day/Year)		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expi (Moi	6. Date Exercisable a Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Pric Deriva Securi (Instr.	itive der ity Sec 5) Ber Ow Foll Rep Trai	Number of rivative curities neficially rned llowing ported insaction(str. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)	
					Code	v	(A) (D)	Date Exe	) rcisable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.91 to \$22.56 inclusive. The Reporting Person undertakes to 2. ...e price reported in Column 4 is a weighted average price. These snares were sold in multiple transactions at prices ranging from \$21.91 to \$22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

/s/ Jason Minio, Attorney-in-

10/04/2024

<u>Fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.